Status update on clinical trial for the treatment of relapsed prostate cancer patients
The pandemic has led to a significant slowdown in SpectraCure's clinical activities. Several hospitals suspended the conduct of studies for an extended period of time and SpectraCure staff have been prevented from travelling due to travel bans in the countries where the study is being conducted. The clinical study protocol involves a number of follow-up […]
Investor Letter July 2021
Ingemar Kihlström, Chairman of the Board, and Johan Folkunger, CEO, reflect on a strong commitment and combined expertise and Homer Pien, recently appointed Board member of SpectraCure, is introduced. Investor letter July 2021 is attached. For further information, please contact: Johan Folkunger, SpectraCures CEO, e-mail: jf@spectracure.com Please also visit, www.spectracure.com SpectraCure is developing a treatment […]
SpectraCure AB publishes Quarterly Report 1, 2021
First quarter 2021 Figures for 2021 and 2020 refer to the Group. Other operating income amounted to KSEK 1,597 (1,185) Result after taxes amounted to KSEK -4,773 (-3,784) Basic and diluted earnings per share: SEK -0.05 (-0.04) Cash flow for the period amounted to KSEK -4,309 (-3,624) Solidity: 92 (86)% […]
The Nomination Committee’s proposal for election of board members in SpectraCure AB
The Nomination Committee has decided to propose the re-election of Board members Ingemar Kihlström, Katarina Svanberg, Sune Svanberg, Ulf Bladin and Hans Bornemark at the Annual General Meeting of SpectraCure AB (publ) on Tuesday 18 May 2021. Ingemar Kihlström is proposed for re-election as Chairman of the Board. Masoud Khayyami, current Board Member, has declined […]
Johan Folkunger appointed new CEO of SpectraCure AB
The Board of Directors of SpectraCure has appointed Johan Folkunger new CEO, with a clear mandate to prepare and lead the Company into the next phase, commercialization. Johan Folkunger has held senior positions in a number of life science and medical technology companies, most recently as responsible for the Medical Technology business area at the […]
Status update regarding clinical studies for the treatment of patients with recurrent prostate cancer
Following the discussions at Investigator Meetings during November 2020 – February 2021, in which doctors and representatives of the clinics included in the company's clinical study participated, a status update follows in light of the current pandemic. Participating hospitals are University College London Hospital, Princess Margaret Cancer Centre in Toronto, University of Pennsylvania Hospital in […]
Positive discussions at SpectraCure’s Investigator Meeting
SpectraCure has held an Investigator Meeting where the topic of discussion was statistics and results from the treatments conducted in the Company's clinical study. The discussions at the meeting will also form the basis of the forthcoming application for Accelerated Approval. Physicians and representatives of the hospitals included in the study participated in the meeting: […]
Interim Report Q3, 2020
Third quarter 2020 Figures for 2020 and 2019 refer to the Group. Other operating income amounted to KSEK 1,656 (692) Result after taxes amounted to KSEK -2,348 (-3,054) Basic and diluted earnings per share: SEK -0.02 (-0.04) The cash flow from operating activities was KSEK -5,300 (-3,072 Nine months, Jan-Sep 2020 Figures for 2020 and […]
Looking for excellent, highly-skilled education and training in the vibrant field of Biophotonics? Apply now!
Apply to The European Training Network PHAST (Photonics for Healthcare: multiscAle cancer diagnosiS and Therapy). Maybe you will be one of 15 Early Stage Researchers (ESRs) which will be enrolled in a strong multidisciplinary PhD programme. Position #12 is at SpectraCure Development of advanced online dosimetry algorithms for photodynamic therapy of tumours. Brief description of […]
Interim Report Q2, 2020
Second quarter 2020 All figures for 2020 and 2019 refer to the Group.Other operating income amounted to kSEK 872 (663) Result after taxes amounted to kSEK -4,810 (-4,149) Basic and diluted earnings per share: SEK -0.05 (-0.05) The cash flow from operating activities was kSEK -5,775 (-3,547) First half of 2020 Other operating income […]
